Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

2020 ◽  
Vol 26 (16) ◽  
pp. 4216-4224 ◽  
Author(s):  
Yuqin Song ◽  
Keshu Zhou ◽  
Dehui Zou ◽  
Jianfeng Zhou ◽  
Jianda Hu ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Selective Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell

scholarly journals The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review

2021 ◽  
Vol 23 (2) ◽  
pp. 253-255
Author(s):  
Kamil D. Kaplanov
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Selective Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell

The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohematology took part in the meeting.

The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma

2020 ◽  
Vol 26 (5) ◽  
pp. 1190-1199
Author(s):  
Kirollos S Hanna ◽  
Maren Campbell ◽  
Alex Husak ◽  
Sabrina Sturm
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Cell Lymphoma ◽  
Bruton’S Tyrosine Kinase ◽  
Front Line ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell

Mantle cell lymphoma is a rare subtype of B-cell non-Hodgkin’s lymphomas that is generally classified as an aggressive lymphoma requiring front-line chemo-immunotherapy with stem cell rescue. Despite effective treatment, many patients relapse or are refractory to front-line therapy. In addition, these patients may also develop drug resistance requiring novel modalities for subsequent lines. Bruton’s tyrosine kinase inhibitors have demonstrated a well-tolerated safety and efficacy profile across several B-cell malignancies. Ibrutinib, acalabrutinib, and zanubrutinib are FDA-approved as treatment options for patients with Mantle cell lymphoma following one prior line of therapy. Various factors should be considered which include the adverse event profile of these agents and ability to adhere to therapy. In this article, we review the role of Bruton’s tyrosine kinase inhibitors for the management of Mantle cell lymphoma and review the clinical pharmacology, pharmacokinetics, safety and efficacy, and future directions.

scholarly journals Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells

2019 ◽  
pp. molcanres.0256.2018 ◽  
Author(s):  
Seung-Cheol Lee ◽  
Alexander A Shestov ◽  
Lili Guo ◽  
Qian Zhang ◽  
Jeffrey C. Roman ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Bruton’S Tyrosine Kinase ◽  
Lymphoma Cells ◽  
Bruton's Tyrosine Kinase ◽  
Kinase Inhibition ◽  
Tyrosine Kinase Inhibition ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document